Clearside Biomedical, INC 10-Q quarterly reports

Clearside Biomedical reports significant financial challenges, including a going concern warning and a strategic review, despite reduced net losses.

Clearside Biomedical reports significant losses, a going concern warning, and a workforce reduction while actively exploring strategic alternatives and facing Nasdaq delisting.

Clearside Biomedical announces its Q1 2025 financial results, highlighting a net loss of $8.2 million and progress in its CLS-AX clinical program for wet AMD.

Clearside Biomedical announced positive topline results from its Phase 2b ODYSSEY trial for CLS-AX in wet AMD and provided a financial update for the third quarter of 2024, highlighting ongoing research and development efforts and financial challenges.

Clearside Biomedical reported a net loss of $19.4 million for the first half of 2024 and faces substantial doubt about its ability to continue as a going concern.

Clearside Biomedical's first quarter 2024 results show increased operating expenses due to ongoing clinical trials, alongside a net loss, but also highlight a recent capital raise and progress in their clinical programs.